Loading Curie Briefs...
Getting the latest healthcare news for you
Getting the latest healthcare news for you
A CDC-led investigation found 12 deaths and dozens of severe adverse events tied to ceftriaxone injections at healthcare facilities across 18 states over 11 months. No tampering, contamination, or product quality issues were found. Researchers believe the initial cluster of deaths may have been a chance grouping of known — but rare — severe reactions to the common antibiotic.
A CDC-led investigation published in Clinical Infectious Diseases has identified 12 deaths and multiple severe adverse events (SAEs) linked to ceftriaxone injections at healthcare facilities across 18 states over an 11-month period. The probe was triggered in December 2024 after an Alabama coroner reported two unexpected deaths following ceftriaxone injections at separate primary care clinics within a single week.
By February 2025, the investigation went national, calling for reports of deaths or cases requiring CPR within six hours of a ceftriaxone injection. Of 56 SAEs reported between August 2024 and September 2025, 31 were classified as serious cases — 12 of which resulted in death. Anaphylaxis-type reactions were common, and many patients had cardiac comorbidities or were on beta-blockers.
Crucially, product testing found no evidence of tampering, adulteration, or contamination, and national adverse event trends remained stable over time — suggesting the initial deaths were likely a chance clustering of known, rare reactions rather than a systemic safety failure.
By the Numbers:
Why it matters: Ceftriaxone is one of the most widely used antibiotics in the U.S. While no product defect was found, this investigation underscores the importance of monitoring for severe reactions — especially in older patients with heart conditions — and maintaining vigilance even when adverse events appear sporadic.
